The AEGIS-II trial evaluated the impact of ApoA1 product CSL112 on cardiovascular death, myocardial infarction (MI), or stroke in patients with MI and additional risk factors. Results showed no significant reduction in the primary endpoint, but a trend toward benefit in cardiovascular death and MI. Exploratory analysis revealed significant benefits in patients with higher LDL levels, but not in those with lower LDL levels. The therapy showed promise in reducing MI, particularly type 4b MI associated with stent thrombosis. The study maintains support for the HDL hypothesis, suggesting the importance of targeting patients with hyperlipidemia for potential benefit.
Source link
ApoA1 Trial Misses Endpoint, But HDL Hypothesis Still Alive?
